The Other Fish In The Sea: AstraZeneca Buys Omthera

AstraZeneca agreed to pay $260 million plus contingency payments to acquire Omthera, the makers of the omega-3 product Epanova, which is ready for regulatory filing for dyslipidemia. The deal raises questions for Amarin, whose similar product Vascepa has reached the market without a big pharma partner.

AstraZeneca PLC announced plans to buy Omthera Pharmaceuticals Inc., the maker of a late-stage fish oil product for dyslipidemia. The deal announced May 28 bypasses Omthera’s rival Amarin Pharmaceuticals Inc., which already has a similar product on the market and has been looking for a big pharma partner or buyer.

AstraZeneca agreed to pay Omthera $12.70 per share, or approximately $323 million, an 88% premium over Omthera’s closing price on May 24. The enterprise value of the deal is lower,...

More from Clinical Trials

More from R&D

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By 

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.

ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials

 
• By 

ISRCTN’s systems are being redesigned to facilitate compliance with upcoming requirements in the UK’s clinical trials legislation.